Markets are Closed
Company Logo
BMY
Bristol-Myers Squibb Company

Open

Previous Open

High

61.22

Previous High

Low

60.07

Previous Low

Close

60.13

Previous Close

Volume

13,242,432

Previous Volume

Company Profile

Description

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

Exchange

New York Stock Exchange

List Date

January 03, 1977

CEO

Giovanni Caforio

Employees

23,700

Financials

Revenue

26.14B

Earnings

4.95B
24B
19B
13B
7B
1B
2015
2016
2017
2018

Splits

August 06, 20010.95%
March 01, 19990.50%

Dividends

August 03, 2020$0.45
May 01, 2020$0.45
November 01, 2019$0.41
August 01, 2019$0.41
May 01, 2019$0.41
February 01, 2019$0.41
November 01, 2018$0.40
August 01, 2018$0.40
May 01, 2018$0.40
February 01, 2018$0.40
November 01, 2017$0.39
August 01, 2017$0.39
May 01, 2017$0.39
February 01, 2017$0.39
November 01, 2016$0.38
August 01, 2016$0.38
May 02, 2016$0.38
February 01, 2016$0.38
November 02, 2015$0.37
August 03, 2015$0.37
May 01, 2015$0.37
February 02, 2015$0.37
November 03, 2014$0.36
August 01, 2014$0.36
May 01, 2014$0.36
February 03, 2014$0.36
November 01, 2013$0.35
August 01, 2013$0.35

Related News

News post image: Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
Mar 27, 2020 @ 15:05
BMS Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA for the Treatment.......
finance yahoo
News post image: Bristol-Myers Wins Green Light for New MS Drug
Bristol-Myers Wins Green Light for New MS Drug
Mar 26, 2020 @ 14:22
Bristol-Myers Squibb will delay a sales push for its newly approved multiple sclerosis drug amid the coronavirus crisis....
finance yahoo
News post image: Bristol-Myers Squibb's new MS drug is approved, launch delayed due to COVID-19
Bristol-Myers Squibb's new MS drug is approved, launch delayed due to COVID-19
Mar 26, 2020 @ 11:57
Shares of Bristol-Myers Squibb Co. gained 1% in premarket trading on Thursday after the drugmaker said the Food and Drug Administration had approved Zeposia, its oral multiple sclerosis drug. However, the company is delaying the launch of the drug as a result of the COVID-19 outbreak, saying doing so is in the best interest of patients, customers, and employees. The drug outperformed Biogen's Avonex in two clinical trials when examining the annualized relapse rate and the number and size of brain lesions, BMS said, and the European Medicines Agency is expected to make its decision on Zeposia in the first half of the year. A company spokesperson said the company would finalize the price of Zeposia when it is launched. Bristol-Myer's stock is down 23% year-to-date, while the S&P 500 has also tumbled about 23%....
finance yahoo
News post image: Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020
Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020
Mar 26, 2020 @ 10:58
Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020...
finance yahoo
News post image: U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
Mar 26, 2020 @ 10:30
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis...
finance yahoo
News post image: Will The FDA Approve Bristol's MS Drug? Here Are Some Bullish Indicators
Will The FDA Approve Bristol's MS Drug? Here Are Some Bullish Indicators
Mar 25, 2020 @ 20:17
The Food and Drug Administration could approve Bristol Myers Squibb's new multiple sclerosis treatment, dubbed ozanimod, on Wednesday — in a move that would likely prod BMY stock to pop....
finance yahoo
News post image: China Suspends Use of BeiGene Cancer Drug Abraxane
China Suspends Use of BeiGene Cancer Drug Abraxane
Mar 25, 2020 @ 18:45
China suspended the use of a BeiGene cancer drug, Abraxane. BeiGene, which gets the drug from Bristol-Myers, said the problem stems from a Bristol-Myers contract manufacturing plant in the U.S....
finance yahoo
News post image: China suspends Bristol-Myers' cancer drug sales over findings at U.S. plant
China suspends Bristol-Myers' cancer drug sales over findings at U.S. plant
Mar 25, 2020 @ 13:58
The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday. Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers&...
finance yahoo
News post image: Bristol Myers puts new clinical trials on hold due to coronavirus
Bristol Myers puts new clinical trials on hold due to coronavirus
Mar 23, 2020 @ 15:09
U.S. drugmaker Bristol Myers Squibb Co said it will put off beginning new clinical trials for at least three weeks because of the impact of the fast-spreading coronavirus pandemic. The company posted a message to clinical trial investigators on its website on Friday, saying it will not initiate any...
finance yahoo
News post image: Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
Mar 23, 2020 @ 10:59
Bristol-Myers Squibb Postpones April 2, 2020 Investor Day...
finance yahoo